Orchestra BioMed Holdings financials
$6.08+3.23%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $33.5M | $2.6M | $2.8M |
| Gross profit | $33.3M | $2.4M | $2.6M |
| Gross margin | 99.4% | 92.3% | 93.3% |
| Operating income | -$51.8M | -$64.3M | -$51.5M |
| Net income | -$53.0M | -$61.0M | -$49.1M |
| Net margin | −158.2% | −2313.3% | −1779.7% |
| Diluted EPS | $-1.11 | $-1.66 | $-1.48 |
| EBITDA | -$51.5M | -$64.0M | -$51.2M |
| Operating cash flow | -$49.0M | -$50.6M | -$46.1M |
| Free cash flow | -$49.5M | -$50.8M | -$46.2M |
| Diluted shares | 47.7M | 36.8M | 33.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $34.7M | $22.3M | $30.6M |
| Short-term investments | $71.8M | $44.6M | $57.0M |
| Total debt | $14.3M | $14.3M | $0.00 |
| Total assets | $114.9M | $76.2M | $95.2M |
| Total liabilities | $51.5M | $43.2M | $27.2M |
| Shareholders' equity | $63.4M | $33.0M | $68.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology